Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
May 22, 2026 7:28 AM
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented, "HARMONi-3 skepticism may ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
